BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan
Completed
- Conditions
- Non-Hodgkin's Lymphoma (NHL)
- Interventions
- Drug: [111]In-ibritumomab tiuxetan (Zevalin, BAY86-5128)
- First Posted Date
- 2011-11-24
- Last Posted Date
- 2011-11-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 72
- Registration Number
- NCT01479387
Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862
Phase 1
Completed
- Conditions
- Clinical Pharmacology
- Interventions
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Bayer
- Target Recruit Count
- 67
- Registration Number
- NCT01473108
Hepatocellular Carcinoma Registry for Turkey (3K Trial)
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Other: No Intervention
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 600
- Registration Number
- NCT01473121
Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study
Phase 3
Completed
- Conditions
- Hypertension, Pulmonary
- Interventions
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 27
- Registration Number
- NCT01469169
A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712)
Phase 4
Completed
- Conditions
- Rhinitis
- Interventions
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2015-03-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 255
- Registration Number
- NCT01469234
Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System
Completed
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Other: Iloprost (Ventavis inhaled, BAYQ6256)
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2014-08-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 38
- Registration Number
- NCT01468545
Placebo and Active Controlled, Double Dummy Study to Compare Efficacy of Aspirin and Ibuprofen in Treatment of Episodic Tension-type Headache
Phase 4
Completed
- Conditions
- Tension-Type HeadacheTension-Type Headache (Episodic)Headache
- Interventions
- First Posted Date
- 2011-11-04
- Last Posted Date
- 2014-12-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1115
- Registration Number
- NCT01464983
Placebo and Active Controlled Study to Compare the Antipyretic Efficacy of Aspirin® in Patients With Acute Febrile Upper Respiratory Tract Infections Suspected to be of Viral Origin
Phase 4
Completed
- Conditions
- Respiratory Tract InfectionsFever
- Interventions
- First Posted Date
- 2011-11-04
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 392
- Registration Number
- NCT01464944
Placebo and Active Controlled Study to Compare the Efficacy of Aspirin and Paracetamol in Treatment of Sore Throat Associated With a Common Cold
Phase 4
Completed
- Conditions
- PharyngitisTonsillitisCommon Cold
- Interventions
- First Posted Date
- 2011-11-04
- Last Posted Date
- 2014-12-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 508
- Registration Number
- NCT01465009
Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2011-10-27
- Last Posted Date
- 2017-10-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 50
- Registration Number
- NCT01460537
© Copyright 2025. All Rights Reserved by MedPath